Lead Product(s) : L-Ornithine L-aspartate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HepaCure (L-Ornithine L-Aspartate) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Acute-On-Chronic Liver Failure.
Product Name : HepaCure
Product Type : Amino Acid
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : L-Ornithine L-aspartate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Ornithine L-aspartate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China
Details : The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.
Product Name : Hepa-Merz
Product Type : Amino Acid
Upfront Cash : Undisclosed
March 08, 2021
Lead Product(s) : L-Ornithine L-aspartate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
